Kessler Topaz Meltzer & Check, LLP Files Securities Class Action Against Edwards Lifesciences Corporation.
Kessler Topaz Meltzer & Check, LLP has announced a securities class action lawsuit against Edwards Lifesciences Corporation (NYSE: EW) in the United States District Court for the Central District of California. This lawsuit is on behalf of investors who acquired Edwards securities between February 6, 2024, and July 24, 2024 (inclusive), also known as the “Class Period.” Investors affected by this case have until December 13, 2024, to seek appointment as lead plaintiff.
The lawsuit alleges that Edwards made misleading statements about the performance and expansion of its Transcatheter Aortic Valve Replacement (TAVR) product. Specifically, the complaint asserts that Edwards misrepresented the condition of its TAVR platform and overestimated its potential for success by relying on inaccurate assumptions about patient populations and healthcare facility willingness to adopt TAVR procedures over newer treatments.
Kessler Topaz Meltzer & Check, LLP is encouraging investors who have experienced significant losses during this Class Period to take action and reach out to the firm for more information. Investors have the option to join the lawsuit and represent the class as a lead plaintiff, or remain absent from the class while still being eligible for any potential recovery. A lead plaintiff represents the interests of the class, working with legal counsel to manage the litigation process.
For more information or to seek appointment as a lead plaintiff, Edwards investors can contact attorney Jonathan Naji, Esq. at (484) 270-1453 or email [email protected]. If you have experienced losses with Edwards, you may CLICK HERE.
The deadline for lead plaintiff appointment is December 13, 2024. Those seeking to participate in the lawsuit should act before this date to ensure they meet the eligibility criteria.
Edwards Lifesciences Corporation is a global leader in heart valve disease and critical care monitoring. Founded in 1958 and headquartered in Irvine, California, the company focuses on innovative medical technologies to address cardiovascular diseases. Edwards is best known for its Transcatheter Aortic Valve Replacement (TAVR) system, a minimally invasive procedure used to treat aortic valve disease, which has become a cornerstone of the company’s business.
The company also provides other products such as heart valve repair solutions, surgical heart valves, and hemodynamic monitoring equipment. Edwards Lifesciences operates in over 100 countries and works closely with healthcare professionals to advance patient care. It is publicly traded on the New York Stock Exchange under the symbol EW. The company’s commitment to innovation and patient outcomes has positioned it as a key player in the medical device industry, particularly in the field of cardiovascular treatment.
Kessler Topaz Meltzer & Check, LLP is dedicated to prosecuting class actions in both state and federal courts across the United States and internationally. The firm has earned a global reputation for excellence, successfully recovering billions for victims of fraud and corporate misconduct. For more information please visit www.ktmc.com.
Robbins LLP Files Class Action Against Rentokil Initial PLC (RTO) Over Failed Terminix Integration